Lime Spyder Racing Team LLC
Links

United States Trotting Association
Illinois Harness Horsemen's Association
Maywood Park
Balmoral Park
Indiana Downs
Hawthorne Race Course
The Meadowlands
Barn To Wire
Horseplop.com
Minnesota Harness Racing
Hoosier Park
Harness Action
Harness Racing TV
Four Footed Fotos
CBS Sportsline
Dave Schmidt's Harness Racing Sale Barn
Harness Racing Videos
Genomed

West Nile Treatment For Horses





















West Nile Trial
West Nile Trial for Horses

GenoMed's patent-pending approach, which uses a class of blood pressure pills to gently reduce excessive inflammation by a patient's own immune system, has achieved a 100% response rate so far among 12 patients with an intact immune system who came down with West Nile virus encephalitis. If GenoMed's approach continues to work in humans (which remains to be seen; 12 is still a small number), it should also work in horses and birds.
Dr. Moskowitz stated; “Essentially there are no side effects. The dose used won’t lower a horse’s blood pressure at all, I should think. The only other side effect of an ARB, namely angioedema, is extremely rare, at least in humans. It occurs in about 1% of humans who use an ACE inhibitor, so in 100 out of 10,000 people who use an ACE inhibitor. Of these, it occurs in only 3 people who then get switched to an ARB. So 3 out of 10,000 is a pretty rare side effect.

If your horse is in need of treatment for West Nile Virus your Veterinarian may contact
Dr. Moskowitz at (dwmoskowitz@genomedics.com)
Website: www.genomedics.com/ people can click on "West Nile trial"
“This is a patent pending approach and anybody who uses it has to get GenoMed's permission to use it first. We’re not charging anything, but we have to make each data point count or it’s a wasted trial.”

You may post this letter on your websites and feel free to pass it along to other groups.
Thanks
Horseshoe Herbals LLC

Contact information:
David W. Moskowitz, MD, MA (Oxon.), FACP
Chairman, CEO and Chief Medical Officer
GenoMed, Inc.

website: www.genomedics.com
ticker symbol: GMED (on OTC Pinksheets)

Address:
909 S. Taylor Ave.
St. Louis, MO 63110
tel. 314-977-0110
FAX 314-754-9772
email: dwmoskowitz@genomedics.com

GenoMed's First Horse Recovers Quickly from Presumed West Nile Virus Encephalitis

FOR IMMEDIATE RELEASE
David W. Moskowitz MD
GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com

ST. LOUIS—July 31, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the first horse in its expanded trial for West Nile virus encephalitis recovered completely within 24 hours after starting GenoMed's treatment.

Four days ago, a horse owner in Idaho contacted GenoMed to say that her horse had begun moving much more slowly, and that the veterinarian was treating it for West Nile virus encephalitis. Only two days before, another of her horses had to be put down for presumed West Nile virus encephalitis because it could no longer lift its head and eat.

Within 24 hours of starting GenoMed's treatment, the horse was "quick on its feet" and appeared fully recovered. The horse's prompt recovery from West Nile virus encephalitis was like that GenoMed has observed since 2003 in people, and since 2004 in birds.

GenoMed's protocol uses a class of already existing blood pressure pills to block the brain inflammation caused by West Nile virus. This disease mechanism appears to be shared by all vertebrates infected with most viruses, leading GenoMed to believe it may have found a safe, general viral antidote. For this reason, GenoMed's approach was included in the language of the Project BioShield II Act of 2005, introduced by Senators Lieberman, Hatch, and Brownback. This bill has not yet been debated in the US Senate.

GenoMed's treatment success rate for WNV encephalitis in people is currently 86% (19 of 22 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "We're delighted that our anti-viral approach appears to work in yet another species. The veterinary community already treats West Nile virus encephalitis as an excessive inflammation of the brain, and is embracing our approach far more readily than the public health community. As a result, I'm afraid that we may save more horses than people this year."
About GenoMed
Anyone can download the human protocol for West Nile virus or avian influenza ("bird flu") for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss specific medications and dosing.

GenoMed's Third Horse with Presumed West Nile Virus Encephalitis Is Better in 24 Hours

FOR IMMEDIATE RELEASE
David W. Moskowitz MD
GenoMed
St. Louis, Missouri
Tel. 314.983.9938
dwmoskowitz@genomed.com

ST. LOUIS—August 21, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed's treatment.

On Thursday afternoon last week, a horse owner in Fresno, California telephoned GenoMed to say that her horse could no longer walk straight and was falling down. The horse had not been vaccinated for West Nile virus, and the diagnosis by the veterinarian was presumed West Nile virus encephalitis.

Within 24 hours of the first dose of GenoMed's treatment, the horse was chasing other horses away from his food, which they had been eating while he was sick.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. As with people, recovery from viral encephalitis usually takes at least a week. Recovery within 24 hours, like GenoMed's three horses and most of GenoMed's human patients, is extremely unusual.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "It's always thrilling to see a clinical trial showing great results. Every trial is really just a gamble. Fortunately, this one seems to be continuing to pay off. All our evidence for the past four years, in humans, birds, and now horses, has been extremely positive."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss dosing.





Privacy Policy/Terms of Service
Merchant policy


 

www.limespyder.com

Powered by CityMax.com